Radiotherapy in the Management of Pituitary Adenomas

Roman O. Kowalchuk, Daniel M. Trifiletti, Paul D. Brown, Jason P. Sheehan

Research output: Chapter in Book/Report/Conference proceedingChapter


The pituitary gland may give rise to a range of etiologically distinct tumors, necessitating a diverse set of multidisciplinary therapeutic approaches. Radiotherapy is clinically indicated in approximately 50% of cancer patients worldwide [1]. Since the advent of highly conformal, stereotactic radiotherapy approaches, stereotactic radiosurgery (SRS) has become a standard treatment option for residual or recurrent nonfunctioning pituitary adenomas [2]. After 5years in retrospective series [3-6], reported local tumor control rates are high, at more than 90%. In the setting of functioning pituitary adenomas, radiosurgery is generally reserved for residual, recurrent, or refractory disease [7]. This chapter details indications, risks, and benefits of pituitary radiotherapy, as well as differences in treatment approaches between SRS, conventionally fractionated external beam radiotherapy, and proton therapy.

Original languageEnglish (US)
Title of host publicationThe Pituitary
Number of pages12
ISBN (Electronic)9780323998994
ISBN (Print)9780323985338
StatePublished - Jan 1 2022


  • Pituitary
  • Radiotherapy
  • Stereotactic radiosurgery

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Radiotherapy in the Management of Pituitary Adenomas'. Together they form a unique fingerprint.

Cite this